Locations:
Search IconSearch
November 26, 2025/Cancer/News & Insight

Artificial Intelligence in Oncology (Podcast)

Real-world applications in clinical documentation and trial matching

There are a number of different ways that artificial intelligence (AI) may be coming into play in the field of oncology.

In a recent episode of the Cancer Advances podcast, Jame Abraham, MD, FACP, Chair of the Department of Hematology & Medical Oncology at the Cleveland Clinic Cancer Institute, joins podcast host Dale Shepard, MD, PhD, to share how AI can impact clinicians' work.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Podcast excerpt:

Dale Shepard, MD, PhD: Can you highlight the things we're doing clinical trial basis. So, one of the hard parts about clinical trials is you see a patient in front of you and you say, "Well, I've got all these trials. What might my patient qualify for?" Maybe highlight a little bit about how we're trying to do trial matching activities.

Jame Abraham, MD: As all of us clearly understand, clinical trial is the gold standard of cancer treatment. And here, in the adults in the US, less than 10% of patients go on clinical trial. And that's due to many reasons. One reason is, as you said, it's so complex to understand the criteria, who meets the criteria, who doesn't meet the criteria.

So, the AI-based technology, Cleveland Clinic is partnering with a company to help us to identify patients who can potentially be eligible for certain trials. And they'll help the clinicians to cut through the noise and select the patients for the trial.

Dale Shepard, MD, PhD: And I guess the good part about that is some of these products, if someone might not have qualified because their white blood cell count was too low, it will go back and then tell you, if those numbers change, whether they're now eligible.

Jame Abraham, MD: Right. Which is huge.

Advertisement

Related Articles

Dr. Thomas Budd
January 28, 2026/Cancer/Innovations
Breast Cancer Vaccine Moves One Step Forward

Phase 1 study demonstrates immune response in three quarters of patients with triple-negative breast cancer

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Ad